Indirect consequences of the COVID-19 pandemic on the healthcare system and the management of other diseases are beginning to emerge.
Blood stem cells have a surprising ability. In addition to ensuring the continuous renewal of blood cells, they keep track of past infections so that faster and more effective immune responses can be triggered in the future.
Driven by Inserm and the Directorate for Research, Studies, Assessment and Statistics (DREES) of France’s Ministry of Solidarity and Health, in conjunction with their partners (National Institute of Statistics and Economic Studies [INSEE], Public Health Agency, National Center for Scientific Research [CNRS], National Institute for Demographic Studies [INED], Université Paris-Saclay), EpiCOV is a large-scale epidemiological study based on a major statistical survey. It is proposing global and scientifically reliable...
Inserm has played a leading role in the French and international research spheres, rallying its many experts in subjects related to fundamental research, therapeutic research, and modelling. Participating also in France’s solidarity effort, the Institute has taken action to distribute tens of thousands of masks, gloves, gowns, shoe covers and reagents to medical teams working in the nation’s hospitals.
For a deeper insight into the social and epidemiological challenges posed by the exceptional prevention measures taken in response to the COVID-19 pandemic – particularly confinement – a multidisciplinary group of researchers has joined forces with Inserm and the Public Health Agency to launch a survey of around 200,000 participants from five major French cohorts.
Furthering scientific knowledge knows no frontiers. Therefore, Inserm would like to reaffirm that the countries of Africa are – more than ever – key scientific partners
The teams of the Infectious and Tropical Diseases Hospital Bichat AP-HP and the University Hospital of Bordeaux, in collaboration with researchers from University of Paris, Inserm IAME UMRS-1137 (University of Paris / INSERM / University Sorbonne Paris Nord), the Institut Pasteur, the Hospices Civils de Lyon, CNRS - UMR 5308, Ecole Normale Supérieure de Lyon and University Claude Bernard Lyon, published a study based on the monitoring of the...
Inserm has joined forces with telecommunications company Orange to study the impact of confinement on population mobility and explore how using aggregated cellphone data could improve COVID-19 pandemic predictions.
A European clinical trial to evaluate four experimental treatments for COVID-19 starts this weekend. Coordinated by Inserm as part of the Reacting consortium, this trial will include at least 800 French patients with severe forms of COVID-19.
At a time when the Sars-CoV-2 epidemic is continuing to spread, France’s Alliance for Life Sciences and Health (Aviesan) is mobilizing to accelerate research into the virus and COVID-19 disease through REACTing – a consortium coordinated by Inserm. The Scientific Advisory Board of REACTing has selected 20 scientific initiatives covering diverse fields, from mathematical modelling to disease prevention and treatment.